A large meta-analysis revealed that withdrawal symptoms from antidepressants are less common than previously believed but still present a real concern. The study, published in The Lancet Psychiatry, found that 14% of individuals who discontinued antidepressants experienced withdrawal symptoms such as dizziness, headaches, nausea, insomnia, and irritability. This figure is lower than some researchers anticipated.
Antidepressants are widely prescribed in affluent countries, including the United States, Canada, the United Kingdom, and much of Western Europe. The controversy surrounding the effects of discontinuing these drugs, not typically intended for long-term use, has persisted since their introduction in the 1950s.
The new study, encompassing 79 scientific studies with 21,002 adult participants, indicates that withdrawal symptoms occur in roughly one in six people stopping antidepressants. This incidence rate is lower than anticipated by some researchers.
Expert Opinions on the Study
The researchers estimate that around one in seven people reported experiencing at least one symptom after stopping antidepressants, while about one in 35 reported severe symptoms. Sameer Jauhar, a psychiatrist at King’s College London not involved in the study, expressed relief at the lower-than-expected withdrawal rates. He asserted, “It will be gratifying to know rates of withdrawal are nowhere near as high as reported [at around 50%].” Lead author Christopher Baethge, a psychiatrist at the University of Cologne in Germany, emphasized that withdrawal symptoms, despite the lower prevalence, are real and patients need to be informed, monitored, and helped if it happens to them. “Withdrawal symptoms are genuine and necessitate patient awareness and support.”
The comprehensive analysis, which included randomized control trials and observational studies from 1961 to 2019, noted that severe symptoms were rare, affecting about one in 35 individuals. Eric Ruhé from Radboud University Medical Center, also not part of the study, highlighted the importance of taking severe symptoms seriously due to the widespread use of antidepressants. He said, “Severe discontinuation symptoms occur much less, but should be taken seriously, and are important as many millions of patients take antidepressants,”
The analysis identified desvenlafaxine, venlafaxine, imipramine, and escitalopram as medications frequently associated with withdrawal symptoms. Conversely, fluoxetine and sertraline exhibited the lowest rates of discontinuation symptoms.
It remains unclear how long withdrawal symptoms might last, but Baethge indicated that research suggests “they often resolve after two to six weeks, or when antidepressants are resumed.”
Also read: Your Energy Drink Could Be Linked With Cardiac Arrest, Here’s Why?
Most antidepressants are selective serotonin reuptake inhibitors (SSRIs), which increase serotonin levels in the brain. The exact mechanism of withdrawal symptoms remains unclear, but one theory suggests that stopping SSRIs reduces serotonin, leading to these symptoms. SSRIs work by blocking serotonin reuptake in the brain, thereby increasing serotonin levels. Scientists theorize that withdrawal symptoms may occur when this increased serotonin is abruptly reduced.
Fluctuations in serotonin signaling can affect sensory perception, emotional states, and sleep-wake cycles, but the exact mechanisms behind specific withdrawal symptoms like dizziness, headaches, or insomnia remain unclear. Some researchers have criticized oversimplified theories linking serotonin to depression, advocating for more comprehensive models.
Placebo Group Findings and the ‘Nocebo’ Effect
The study also found that nearly 20% of individuals in placebo groups reported symptoms similar to those discontinuing antidepressants, possibly due to a “nocebo” effect, where expecting negative outcomes heightens awareness of symptoms. Baethge suggested that these findings point to a “background noise” of non-specific symptoms common in everyday life.
The study concludes that while antidepressant withdrawal symptoms are less prevalent than once thought, they are significant and need careful management. The findings highlight the importance of supporting patients through the discontinuation process and addressing symptoms seriously, irrespective of their cause.
